SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending as traders discuss its potential for a significant breakout, drawing comparisons to other Hong Kong-based stocks with crypto tie-ins that have recently seen substantial gains. Community members are closely watching the low float and anticipating news, particularly regarding the company's previously announced plans for a crypto treasury. Bullish investors hope CLIK can mirror the success of similar plays, while others express concerns about its ability to execute and sustain momentum.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending amid discussions around Amazon's competitive moves and their potential impact on the ad-tech landscape; the community is debating the validity of recent reports and the company's long-term prospects in light of these challenges. Some investors view the dip as a buying opportunity, while others express concern over the stock's performance and potential market manipulation. The company's response and upcoming earnings are key points of focus.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

Picard Medical (PMI) is trending amid significant stock volatility, prompting the company to release a statement clarifying they are unaware of any undisclosed material changes. The community is actively discussing potential dilution, short covering, and speculating about a possible pump and dump, while some remain bullish, citing the company's unique position in the artificial heart market.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending due to an FDA investigation into increased reports of allergic reactions to specific lots of intravenous immunoglobulin (IGIV) products, including two ADMA lots, leading to a voluntary recall. While some community members view this as a buying opportunity, citing the company's strong fundamentals and potential for a pre-earnings run-up, others are concerned about potential impacts on future earnings and are closely watching for management's response and share buyback activity. The community is also discussing the broader context of hypersensitivity reactions to IGIV drugs and ADMA's growth potential within the plasma-derived therapies market.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a significant surge, with the community citing recent insider buying activity as a possible catalyst. Discussions also mention a milestone payment from Merck related to their Alzheimer's program. Some traders are closely watching the low float and suggesting a potential short squeeze, while others express caution due to potential dilution.

Meet DragonWifBeard: The world's first AI-powered pet dragon!  More Than Just Scales: DragonWifBeard is a real-life bearded dragon revolutionizing the pet experience. He's not just any reptile – he's equipped with cutting-edge Eliza AI agent, giving him a unique personality and the ability to interact with his environment in unprecedented ways. The Future of Companionship: This groundbreaking project merges the love for pets with the limitless possibilities of AI. Witness the dawn of a new era in companionship with DragonWithBeard.

DragonWifBeard

DragonWifBeard ($DWB) is gaining attention, with community members promoting it as the next big opportunity. Conversations highlight its availability on Phantom Wallet and its potential for significant gains. The coin is frequently mentioned alongside other popular cryptocurrencies like Bitcoin, Solana, and Shiba Inu.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BBIO is trending as investors discuss upcoming Phase 3 results and the potential of new drugs in its portfolio, with readouts anticipated before Thanksgiving. Community members are also weighing the long-term potential of the stock, considering its current market cap and future growth prospects. Bullish sentiment is fueled by the protective hedging strategy and possible new drug additions, while others are eyeing call options.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as traders discuss a potential short squeeze, noting high borrowing costs and a seemingly limited float. Community members are debating the impact of insider activity and monitoring short interest data. Some investors suggest a buy-and-hold strategy, while others point to technical indicators.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

Slap is trending as the community rallies around the coin's real-world partnerships and sponsored pro athletes.  Discussions highlight the team's grindset mentality and the coin's universal appeal as more than just a meme.  The project's unique branding and active community involvement are also key talking points.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto is trending as the community discusses its potential for significant gains due to its limited supply and recent price movements. Some users point to technical analysis, highlighting breakout patterns, while others speculate about a possible Coinbase listing and its impact on the token's value. The conversation also mentions the broader ecosystem and related tokens.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.75, marking a -5.89% move from the previous day.

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.36, moving 6.33% from the previous trading session.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.23, representing a -5.42% change from its previous close.

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.98, representing a +1.32% change from its previous close.

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $4.77, signifying a -1.24% move from its prior day's close.

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

RXRX
Recursion Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RXRX News

RXRXRecursion Pharmaceuticals Inc